Xilio Therapeutics, Inc.
XLOXilio Therapeutics, Inc. in brief
Xilio Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Waltham, Massachusetts, USA. Its market value was $57 M on 29 October 2026, which makes it the 20,852nd largest listed company in the world and the 3,808th largest in the USA on this site. In the year to December 2025 it had sales of $44 M and a net loss of $35 M. It employs about 76 people and Rene Russo is its chief executive. Its shares trade under the symbol XLO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Xilio Therapeutics, Inc.
We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer. Leveraging our clinically-validated masking technology and capabilities, we are developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Our integrated biology and protein engineering approach enables us to design and develop highly potent, masked biologics that are activated, or unmasked, by tumor-specific proteases within the tumor microenvironment. We are currently advancing multiple programs in preclinical and clinical development, including masked multi-specifics, and our clinically-validated masking technology has enabled us to establish top-tier strategic partnerships, including with AbbVie Group Holdings Limited, or AbbVie, and Gilead Sciences, Inc., or Gilead.
From the company's annual report filed with the US SEC: read the report
Xilio Therapeutics, Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 22 October 2021; shares registered for exchange trading on 18 October 2021.
Events of Xilio Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,176 (Jan 2022) · #4,601 (Dec 2022) · #4,418 (Jul 2023) · #4,363 (Jan 2024) · #2,195 (Mar 2026) · #3,675 (Aug 2026) · #3,730 (Oct 2026) · #3,812 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.0×
- Price / book
- 1.6×
- Free cash flow yield
- -9.7%
- Net margin (TTM)
- -20.9%
- Operating margin
- -95.9%
- Return on equity
- -32.6%
- Liabilities / assets
- 77.2%
- Revenue growth
- +590.4%
- R&D / revenue
- 128.0%
- Revenue per employee
- $576 K
- Profit per employee
- $-461 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $44M | +590.4% | $-42M | $-35M | -80.1% |
| Dec 2024 | $6M | — | $-61M | $-58M | -918.6% |
| Dec 2023 | — | — | $-79M | $-76M | — |
| Dec 2022 | — | — | $-89M | $-88M | — |
| Dec 2021 | — | — | $-75M | $-76M | — |
| Dec 2020 | — | — | $-55M | $-55M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-5M | $1M | $-6M | $-4.19 | — |
| Dec 2024 | $-18M | $0M | $-18M | $-15.24 | — |
| Dec 2023 | $-69M | $0M | $-69M | $-2.78 | — |
| Dec 2022 | $-76M | $2M | $-78M | $-3.22 | — |
| Dec 2021 | $-81M | $1M | $-82M | $-13.52 | — |
| Dec 2020 | $-36M | $2M | $-38M | $-105.42 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $10M (-47.7% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jun 12, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 28, 2026DEF 14AProxy statement
- Apr 16, 20268-KCurrent reportDirectors or officers changed
- Mar 23, 202610-KAnnual report · period to Dec 2025
- Mar 23, 20268-KCurrent reportResults of operations
- Mar 12, 20268-KCurrent reportBylaws amended
Official filings of Xilio Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $44 M
- Operating income
- $-42 M
- Net income
- $-35 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $155 M
- Total liabilities
- $119 M
- Total equity
- $35 M
As of December-2025
Top 29 institutional investors in Xilio Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Bain Capital Life Sciences Investors, LLC | 664,021 | 0 (0.00%) | 9.40% | $6 M | Nov 16, 2026 |
| 2 | Orbimed Advisors LLC | 592,300 | 0 (0.00%) | 8.38% | $5 M | Nov 16, 2026 |
| 3 | Adage Capital Partners GP, L.L.C. | 464,598 | +353,057 (+316.53%) | 6.58% | $4 M | Nov 16, 2026 |
| 4 | Frazier Life Sciences Management, L.P. | 422,505 | 0 (0.00%) | 5.98% | $4 M | Nov 16, 2026 |
| 5 | Vanguard Capital Management LLC | 198,181 | +19,664 (+11.02%) | 2.81% | $2 M | Nov 13, 2026 |
| 6 | Stonepine Capital Management, LLC | 189,092 | -36,902 (-16.33%) | 2.68% | $2 M | Nov 13, 2026 |
| 7 | Sio Capital Management, LLC | 152,464 | 0 (0.00%) | 2.16% | $1 M | Nov 16, 2026 |
| 8 | Merck & Co., Inc. | 105,982 | 0 (0.00%) | 1.50% | $1 M | Nov 13, 2026 |
| 9 | Renaissance Technologies LLC | 63,553 | -600 (-0.94%) | 0.90% | $1 M | Nov 12, 2026 |
| 10 | Morgan Stanley | 53,674 | -3,280 (-5.76%) | 0.76% | $0 M | Nov 13, 2026 |
| 11 | Geode Capital Management, LLC | 41,449 | +2,394 (+6.13%) | 0.59% | $0 M | Nov 6, 2026 |
| 12 | Two Sigma Investments, LP | 40,104 | +25,560 (+175.74%) | 0.57% | $0 M | Nov 16, 2026 |
| 13 | Vanguard Fiduciary Trust Co | 28,193 | +5,599 (+24.78%) | 0.40% | $0 M | Nov 13, 2026 |
| 14 | Bridgeway Capital Management, LLC | 17,544 | 0 (0.00%) | 0.25% | $0 M | Nov 16, 2026 |
| 15 | Gsa Capital Partners LLP | 16,673 | +3,083 (+22.69%) | 0.24% | $0 M | Nov 16, 2026 |
| 16 | State Street Corp | 13,311 | 0 (0.00%) | 0.19% | $0 M | Nov 12, 2026 |
| 17 | Prudential Financial Inc | 13,180 | New | 0.19% | $0 M | Nov 16, 2026 |
| 18 | HRT Financial LP | 12,453 | New | 0.18% | $0 M | Nov 13, 2026 |
| 19 | Northern Trust Corp | 11,650 | New | 0.16% | $0 M | Nov 16, 2026 |
| 20 | Citadel Advisors LLC | 11,061 | -14,889 (-57.38%) | 0.16% | $0 M | Nov 16, 2026 |
| 21 | BlackRock, Inc. | 10,908 | +2,151 (+24.56%) | 0.15% | $0 M | Nov 13, 2026 |
| 22 | Vanguard Global Advisers, LLC | 3,359 | New | 0.05% | $0 M | Nov 13, 2026 |
| 23 | Steward Partners Investment Advisory, LLC | 714 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 24 | UBS Group AG | 544 | +530 (+3785.71%) | 0.01% | $0 M | Nov 10, 2026 |
| 25 | Royal Bank Of Canada | 98 | New | 0.00% | $0 M | Nov 16, 2026 |
Show all 29: investors 26 to 29
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Tower Research Capital LLC (TRC) | 94 | New | 0.00% | $0 M | Nov 16, 2026 |
| 27 | Key Financial Inc | 59 | 0 (0.00%) | 0.00% | $0 M | Nov 2, 2026 |
| 28 | Jones Financial Companies Lllp | 58 | +29 (+100.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 29 | Citigroup Inc | 1 | New | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Xilio Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 142,440 | $1 M | 2.0% | <0.01% | +176% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 35,606 | $0 M | 0.50% | <0.01% | −40% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 19,824 | $0 M | 0.28% | <0.01% | new | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 8,219 | $0 M | 0.12% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 7,476 | $0 M | 0.11% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 4,514 | $0 M | 0.06% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 2,768 | $0 M | 0.04% | <0.01% | new | May 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 1,507 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 1,116 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 538 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 471 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 254 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Xilio Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | James Samuel ShannonDirector | Buy | +5,000 | $8.790 | $44 K | 10,000 | Form 4 |
| filed | Kevin M. BrennanSVP, FINANCE AND ACCOUNTING | Sell10b5-1 plan | -1,826 | $0.640 | $1 K | 6,371 | Form 4 |
| filed | Christopher James FrankenfieldChief Financial Officer | Sell10b5-1 plan | -7,030 | $0.640 | $4 K | 24,766 | Form 4 |
| filed | Katarina LuptakovaCHIEF MEDICAL OFFICER | Option exercise | +16,625 | — | — | 33,250 | Form 4 |
| filed | Kevin M. BrennanSVP, FINANCE AND ACCOUNTING | Option exercise10b5-1 plan | +5,000 | — | — | 8,197 | Form 4 |
| filed | Christopher James FrankenfieldChief Financial Officer | Option exercise10b5-1 plan | +19,375 | — | — | 31,796 | Form 4 |
| filed | Rene RussoPRESIDENT AND CEO, Director | Option exercise | +44,250 | — | — | 325,422 | Form 4 |
| filed | James Samuel ShannonDirector | Buy | +25,000 | $0.690 | $17 K | 70,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Xilio Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-9.5 reverse split
Trading halts
- 2026-10-30 15:21 UTC, code LUDP, resumed 15:26 UTC
- 2026-03-13 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 886 shares at $8.01
- : 203 shares at $8.43
- : 581 shares at $8.54
- : 381 shares at $8.55
- : 251 shares at $9.02
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Xilio Therapeutics, Inc. scorecard#
Passes 5 of the 15 checks that could be worked out: strongest in growth (2 of 3), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-9.7%Free cash flow is -9.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth2 of 3
- ✓Revenue grew in the newest year590.4%Revenue up 590.4% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-4.19 vs -15.24Diluted EPS -4.19 in fiscal 2025 against -15.24 the year before (report's currency).
- ✓Net income higher than five years earlier-$35 M-$35 M in fiscal 2025 against -$55 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$35 MNet income -$35 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-95.9%-95.9% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-132.6%-132.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.6×Current ratio 2.58 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-3.43Z-score -3.43 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Xilio Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -95.9% | -60.5% | |
| Net margin | -80.1% | -68.9% | |
| Return on equity | -132.6% | -61.0% | |
| Revenue growth | 590.4% | 15.8% | |
| Free cash flow margin | -12.6% | -61.5% |
4of 7on the Piotroski tests of financial strength
- Net loss of $35 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$6 million.
Xilio Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 44+590%100% | 6.3—100% | — | — | — | — | |
| Research and development | 56+36.0%128% | 41−21.0%650% | 52−11.9%— | 59+15.7%— | 51+16.6%— | 44—— | |
| General and administrative | 30+19.9%67.9% | 25−8.2%391% | 27−9.9%— | 30+25.5%— | 24+124%— | 11—— | |
| Operating expenses | 86+28.1%196% | 67−15.4%1055% | 79−11.2%— | 89+18.8%— | 75+37.5%— | 55—— | |
| Operating income | −42—−95.9% | −61—−955% | −79—— | −89—— | −75—— | −55—— | |
| Other non-operating income (expense) | 6.9+197%15.9% | 2.3−14.2%36.9% | 2.7+194%— | 0.9—— | −0.8—— | −0.7—— | |
| Income before tax | −35—−80.1% | −58—−918% | — | — | — | — | |
| Income tax | 0—0.0% | 0—0.0% | 0—— | 0—— | 0—— | 0—— | |
| Net income including minority interests | −35—−80.1% | −58—−918% | −76—— | −88—— | −76—— | −55—— | |
| Net income attributable to shareholders | −35—−80.1% | −58—−918% | −76—— | −88—— | −76—— | −55—— | |
| Earnings per share, basic | -4.19—— | -15.24r-1.09—— | -2.78—— | -3.22—— | -13.52—— | -105.42—— | |
| Earnings per share, diluted | -4.19—— | -15.24r-1.09—— | -2.78—— | -3.22—— | -13.52—— | -105.42—— | |
| Shares, weighted average (basic) | 8.4+119%— | 3.8r54−86.1%— | 27+0.4%— | 27+389%— | 5.6+970%— | 0.5—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 138+149%88.9% | 55+23.7%77.8% | 45−62.9%73.4% | 120−39.2%86.5% | 198+929%90.8% | 19—53.0% | |
| Other current assets | 2.5−49.5%1.6% | 4.9+44.4%7.0% | 3.4−16.7%5.6% | 4.1−7.9%3.0% | 4.5+10045%2.0% | 0.0—0.1% | |
| Current assets | 145+141%93.8% | 60+25.2%84.7% | 48−61.3%79.0% | 124−38.5%89.5% | 203+884%92.9% | 21—56.7% | |
| Property, plant and equipment | 3.9−13.0%2.5% | 4.5−24.7%6.3% | 5.9−18.1%9.8% | 7.3−4.8%5.2% | 7.6+3.4%3.5% | 7.4—20.3% | |
| Right-of-use (leased) assets | 4.0−13.7%2.6% | 4.6−10.5%6.5% | 5.1−8.2%8.4% | 5.6−6.6%4.0% | 6.0−5.3%2.7% | 6.3—17.4% | |
| Total assets | 155+118%100% | 71+16.7%100% | 61−56.2%100% | 139−36.2%100% | 218+500%100% | 36—100% | |
| Accounts payable | 3.2+23.1%2.0% | 2.6+145%3.6% | 1.1−66.4%1.7% | 3.1−0.6%2.2% | 3.1−42.2%1.4% | 5.4—15.0% | |
| Current liabilities | 56+106%36.4% | 27+70.8%38.4% | 16−24.4%26.2% | 21+65.3%15.2% | 13−42.3%5.9% | 22—61.0% | |
| Lease liabilities (non-current) | 5.6−19.3%3.6% | 7.0−14.6%9.8% | 8.1−11.4%13.4% | 9.2−9.1%6.6% | 10−7.3%4.6% | 11—30.0% | |
| Total liabilities | 119+123%77.2% | 53+122%75.2% | 24−28.1%39.6% | 34+2.7%24.1% | 33−21.6%15.0% | 42—115% | |
| Retained earnings | −419—−271% | −384—−540% | −326—−534% | −249—−179% | −161—−73.8% | −85—−234% | |
| Shareholders' equity | 35+100%22.8% | 18−52.2%24.8% | 37−65.1%60.4% | 106−43.0%75.9% | 185—85.0% | −83—−229% | |
| Total liabilities and equity | 155+118%100% | 71+16.7%100% | 61−56.2%100% | 139−36.2%100% | 218+500%100% | 36—100% | |
| Shares outstanding | 4.5+38.6%— | 3.3r46−88.2%— | 28+0.7%— | 27+0.2%— | 27+3865%— | 0.7—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 1.5−6.3%3.5% | 1.6−13.5%25.9% | 1.9+2.9%— | 1.8+23.2%— | 1.5+40.8%— | 1.1—— | |
| Share-based compensation | 6.9+7.8%15.9% | 6.4−12.8%101% | 7.4−12.4%— | 8.4+69.9%— | 5.0+283%— | 1.3—— | |
| Cash from operating activities | −5.0—−11.4% | −18—−290% | −69—— | −76—— | −81—— | −36—— | |
| Capital expenditure | −0.5—−1.2% | −0.0—−0.6% | −0.5—— | −1.9—— | −1.1—— | −2.2—— | |
| Cash from investing activities | −0.5—−1.2% | −0.0—−0.6% | −0.5—— | −1.9—— | −1.1—— | −2.2—— | |
| Debt issued | — | — | — | — | 1.0—— | — | |
| Debt repaid | — | −3.3—−52.5% | −6.7—— | — | −1.0—— | — | |
| Shares issued | — | — | — | — | 116—— | — | |
| Cash from financing activities | 88+201%201% | 29—460% | −6.6—— | −0.1−100%— | 261+2499%— | 10—— | |
| Change in cash | 82+663%188% | 11—170% | −76—— | −78−143%— | 179—— | −28—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 55+73.0%100% | 10.0−47.6%100% | 19+131%100% | 13+332%100% | 14*+694%100% | 19+743%100% | 8.1+243%100% | 2.9—100% | 1.7*—100% | 2.3—100% | 2.4—100% | — | — | |
| Research and development | 67+44.0%122% | 15+3.4%148% | 15−5.0%77.9% | 20+140%157% | 18*+105%132% | 14+33.1%75.1% | 15+36.7%190% | 8.3−20.5%282% | 8.8*−24.7%513% | 11—475% | 11—476% | 10—— | 12*—— | |
| General and administrative | 29+0.2%52.5% | 6.9+3.8%69.4% | 7.6+7.1%40.8% | 6.9−18.6%54.8% | 7.4*+13.5%54.1% | 6.7+5.8%35.0% | 7.1+22.4%88.1% | 8.5+38.7%291% | 6.5*+1.9%378% | 6.3—279% | 5.8—247% | 6.1—— | 6.4*—— | |
| Operating expenses | 96+27.3%175% | 22+3.5%218% | 22−1.2%119% | 27+59.5%212% | 26*+66.2%186% | 21+23.3%110% | 22+31.6%278% | 17−4.0%573% | 15*−15.3%891% | 17—752% | 17—724% | 17—— | 18*—— | |
| Operating income | −41—−74.9% | −12—−118% | −3.5—−18.7% | −14—−112% | −12*—−86.5% | −1.9—−10.1% | −14—−178% | −14—−473% | −14*—−791% | −15—−652% | −15—−624% | −17—— | −18*—— | |
| Other non-operating income (expense) | 30—54.0% | 5.8—58.1% | −2.9—−15.4% | 4.6+682%36.2% | 22*+4041%162% | −14−2035%−75.3% | −1.5−290%−18.3% | 0.6+106%20.0% | 0.5*+12.8%31.1% | 0.7—32.8% | 0.8—33.1% | 0.3—— | 0.5*—— | |
| Net income including minority interests | −11—−20.9% | −5.9*—−59.6% | −6.4*—−34.1% | −9.5—−75.3% | 10*—75.7% | −16*—−85.4% | −16*—−196% | −13—−453% | −13*—−759% | −14*—−620% | −14*—−591% | −17—— | −18*—— | |
| Net income attributable to shareholders | −11—−20.9% | −5.9—−59.6% | −6.4—−34.1% | −9.5—−75.3% | 10*—75.7% | −16—−85.4% | −16—−196% | −13—−453% | −13*—−759% | −14—−620% | −14—−591% | −17—— | −18*—— | |
| Earnings per share, basic | — | -0.30—— | -0.33—— | -0.58—— | — | -1.58r-0.11—— | -2.30r-0.16—— | -2.49r-0.18—— | — | -0.22—— | -0.24—— | -0.62—— | — | |
| Earnings per share, diluted | — | -0.30—— | -0.33—— | -0.58—— | — | -1.58r-0.11—— | -2.30r-0.16—— | -2.49r-0.18—— | — | -0.22—— | -0.24—— | -0.62—— | — | |
| Shares, weighted average (basic) | 20+91.3%— | 20+91.3%— | 19+182%— | 16+206%— | — | 10r144−83.8%— | 6.9r96−88.1%— | 5.3r75−80.9%— | — | 63—— | 58—— | 28—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 122—90.6% | 122+17.7%90.6% | 136+11.9%88.2% | 150+68.8%92.0% | 138+149%88.9% | 104+69.4%77.6% | 122+62.2%90.8% | 89+162%85.9% | 55+23.7%77.8% | 61—82.1% | 75—83.4% | 34—41.1% | 45—73.4% | |
| Receivables | — | — | — | — | — | — | — | — | — | — | — | 30—36.3% | — | |
| Other current assets | 4.3—3.2% | 4.3+52.8%3.2% | 3.4+58.3%2.2% | 3.9−6.1%2.4% | 2.5−49.5%1.6% | 2.8+37.8%2.1% | 2.2−29.2%1.6% | 4.1−20.7%4.0% | 4.9+44.4%7.0% | 2.1—2.7% | 3.1—3.4% | 5.2—6.3% | 3.4—5.6% | |
| Current assets | 126—93.8% | 126+1.9%93.8% | 145+17.6%94.3% | 154+65.5%94.3% | 145+141%93.8% | 124+96.0%92.8% | 124+58.6%92.5% | 93+34.7%89.9% | 60+25.2%84.7% | 63—84.8% | 78—86.8% | 69—83.7% | 48—79.0% | |
| Property, plant and equipment | 3.1—2.3% | 3.1−16.1%2.3% | 3.4−16.4%2.2% | 3.7−14.2%2.3% | 3.9−13.0%2.5% | 3.7−24.1%2.8% | 4.0−21.8%3.0% | 4.3−22.6%4.1% | 4.5−24.7%6.3% | 4.8—6.5% | 5.1—5.7% | 5.5—6.7% | 5.9—9.8% | |
| Right-of-use (leased) assets | 3.4—2.5% | 3.4−17.0%2.5% | 3.6−15.8%2.3% | 3.8−14.7%2.3% | 4.0−13.7%2.6% | 4.1−12.8%3.1% | 4.3−12.0%3.2% | 4.4−11.2%4.3% | 4.6−10.5%6.5% | 4.7—6.3% | 4.9—5.4% | 5.0—6.1% | 5.1—8.4% | |
| Total assets | 135—100% | 135+0.9%100% | 154+15.3%100% | 163+57.6%100% | 155+118%100% | 134+79.1%100% | 134+48.9%100% | 104+25.6%100% | 71+16.7%100% | 75—100% | 90—100% | 83—100% | 61—100% | |
| Accounts payable | 0.8—0.6% | 0.8−67.3%0.6% | 2.3−43.5%1.5% | 1.1−53.2%0.7% | 3.2+23.1%2.0% | 2.3+137%1.7% | 4.1+224%3.1% | 2.3+205%2.2% | 2.6+145%3.6% | 1.0—1.3% | 1.3—1.4% | 0.7—0.9% | 1.1—1.7% | |
| Current liabilities | 27—19.9% | 27−52.5%19.9% | 34−35.8%22.2% | 43−9.8%26.3% | 56+106%36.4% | 56+48.3%42.2% | 53+37.8%39.8% | 48+50.8%45.9% | 27+70.8%38.4% | 38—50.9% | 39—43.0% | 32—38.2% | 16—26.2% | |
| Lease liabilities (non-current) | 4.5—3.3% | 4.5−24.6%3.3% | 4.9−22.6%3.2% | 5.3−20.8%3.2% | 5.6−19.3%3.6% | 6.0−17.9%4.5% | 6.3−16.7%4.7% | 6.6−15.6%6.4% | 7.0−14.6%9.8% | 7.3—9.7% | 7.6—8.4% | 7.9—9.5% | 8.1—13.4% | |
| Total liabilities | 67—49.4% | 67−53.0%49.4% | 82−35.3%53.2% | 91−2.2%55.6% | 119+123%77.2% | 142+164%106% | 127+124%94.7% | 93+63.6%89.7% | 53+122%75.2% | 54—71.9% | 56—62.8% | 57—68.8% | 24—39.6% | |
| Retained earnings | −441—−327% | −441—−327% | −435—−282% | −428—−262% | −419—−271% | −429—−321% | −413—−309% | −397—−383% | −384—−540% | −371—−496% | −357—−397% | −343—−415% | −326—−534% | |
| Shareholders' equity | 68—50.6% | 68—50.6% | 72+922%46.8% | 73+578%44.4% | 35+100%22.8% | −8.1−139%−6.1% | 7.1−78.8%5.3% | 11−58.5%10.3% | 18−52.2%24.8% | 21—28.1% | 33—37.2% | 26—31.2% | 37—60.4% | |
| Total liabilities and equity | 135—100% | 135+0.9%100% | 154+15.3%100% | 163+57.6%100% | 155+118%100% | 134+79.1%100% | 134+48.9%100% | 104+25.6%100% | 71+16.7%100% | 75—100% | 90—100% | 83—100% | 61—100% | |
| Shares outstanding | 6.6—— | 6.6−87.3%— | 6.6−87.3%— | 5.8−88.8%— | 4.5+38.6%— | 52+17.9%— | 52+17.9%— | 52+50.2%— | 3.3r46−88.2%— | 44—— | 44—— | 34—— | 28—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.3−17.3%2.4% | 0.3*−5.6%3.2% | 0.3*−13.1%1.8% | 0.3−30.8%2.7% | 0.3*−14.1%2.4% | 0.3*−10.5%1.8% | 0.4*−14.4%4.7% | 0.5+12.2%17.0% | 0.4r0.4*−16.3%21.8% | 0.4r0.4*—16.8% | 0.4*—18.9% | 0.4—— | 0.4*—— | |
| Share-based compensation | 8.7+56.7%15.7% | 1.9+70.8%19.2% | 1.6+18.3%8.5% | 2.2+44.0%17.5% | 2.9*+93.3%21.4% | 1.1−28.7%5.9% | 1.4−10.6%16.7% | 1.5−16.3%52.4% | 1.5*−21.5%87.9% | 1.6—69.6% | 1.5—64.1% | 1.8—— | 1.9*—— | |
| Cash from operating activities | −57—−103% | −14*—−138% | −19*—−100% | −22−177%−177% | −2.0*—−14.6% | −17*—−91.8% | −14*−173%−179% | 29—989% | −14*—−821% | −14*—−604% | 20*—847% | −11—— | −13*—— | |
| Capital expenditure | −0.7—−1.3% | −0.1*—−0.6% | −0.0*—−0.1% | −0.6—−4.4% | −0.1*—−0.7% | 0*—0.0% | −0.4*—−5.0% | −0.0—−0.8% | −0.0*—−0.3% | −0.0*—−0.4% | — | — | 0*—— | |
| Cash from investing activities | −0.7—−1.3% | −0.1*—−0.6% | −0.0*—−0.1% | −0.6—−4.4% | −0.1*—−0.7% | 0*—0.0% | −0.4*—−5.0% | −0.0—−0.8% | −0.0*—−0.3% | −0.0*—−0.4% | — | — | 0*—— | |
| Debt repaid | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −3.3—— | −1.7*—— | |
| Cash from financing activities | 76+26.5%138% | 0*—0.0% | 4.5*−90.5%24.0% | 36+639%282% | 36*+337%262% | −0.3*—−1.5% | 47*+136%586% | 4.8+406%165% | 8.2*—476% | −0.0*—−0.1% | 20*—850% | 1.0—— | −1.6*—— | |
| Change in cash | 18−56.6%33.5% | −14*—−139% | −14*−144%−76.4% | 13−62.1%101% | 34*—247% | −18*—−93.3% | 32*−18.7%402% | 34—1153% | −6.0*—−346% | −14*—−605% | 40*—1696% | −9.5—— | −15*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Xilio Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Directors and officers 5 · Material agreement 4 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Directors and officersResults announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Xilio Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2020 for 1 positions, at a median wage of $100 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Scientist, Protease BiologyBiological Scientists, All Other | 1 | $100 K |
Where: Waltham, MA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Xilio Therapeutics
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Xilio Therapeutics, Inc. compares in Biotechnology
- Market cap$57 M · higher than 28% of 726
- Revenue$44 M · higher than 58% of 647
- Net margin-20.9% · higher than 60% of 408
- Revenue growth590.4% · higher than 95% of 438
- Price / sales1.0× · lower than 93% of 339
- Price / book1.6× · lower than 65% of 534
- FCF yield-9.7% · higher than 57% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Xilio Therapeutics, Inc.🇺🇸 | $57 M | — | -20.9% | +590.4% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of February 28, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Xilio Therapeutics, Inc.? Verify and update this profile — free
Show Xilio Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.